BRCA2 and neoplasm: In contrast to other histological types of ovarian cancer, 96% of high-grade serous (HGS)-OvCa samples had TP53 mutations leading to FOXM1 overexpression and 22% of tumours had germline or somatic mutations in BRCA1 and BRCA2. This study also showed that BRCA1 and BRCA2 mutations had a positive impact on survival while BRCA1 epigenetically silenced cases have poorer outcomes.